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Summary The proliferative potential of human solid tumours, in vivo, was investigated using bromodeoxy-
uridine (BrdUrd) incorporation and flow cytometry (FCM). Patients with solid tumours from a variety of
sites were injected with 500mg BrdUrd, intravenously, several hours prior to biopsy or surgical excision. The
labelling index (LI), duration of S-phase (Ts) and thus the potential doubling time (Tpot) could be measured
within 24h of sampling. The results show that both the LI and Ts vary greatly between tumours (Ts ranges
from 5.8 to 30.7h). However, within this study of 26 evaluable patients, tumours of the same tissue origin
tended to have similar Ts values. Melanomas had the shortest Ts (8.8h), nine patients with head and neck
cancer had Ts values ranging from 5.8 to 18.8h (median 12.5h). The longest Ts values (24h) were found in
lung and rectum. The estimates of Tpot ranged from only 3.2 days in an oat cell carcinoma to 23.2 days in a
lymphoma. The striking feature of the study was that 38% of the tumours had a potential doubling time of 5
days or less. We found no relationship between proliferation and histopathological differentiation or DNA
ploidy. It should now be possible to assess the prognostic significance of pretreatment cell kinetic
measurements which may, in the future, aid in the selection of treatment schedules for the individual patient.
The cellular proliferation of human cancer has been the
subject of much study over the years, aimed at rationalising
treatment so that schedules more suited to the cell kinetic
characteristics of individual tumours can be given. However,
progress has been hampered by the nature of the techniques
available to measure cell kinetic parameters. The incidence of
mitotic figures has been used to relate cell production rate to
histological parameters and patient survival (Weiss, 1971).
However, this parameter has failed to demonstrate any
significant correlation with survival. The stathmokinetic
method has been applied to human tumours by several
groups (Meyer & Donaldson, 1969; Camplejohn et al., 1973)
to overcome the inadequacies of mitotic index alone. How-
ever, it is not possible to ensure that maximum mitotic
collection rate is achieved. The most widely used method has
been to measure the labelling index using tritiated thymidine
(3HTdR) and autoradiography. The bulk of the data
obtained using this method have come from labelling tumour
explants or cell suspensions in vitro (see Steel, 1977; Meyer,
1982 for reviews). Some studies have been performed in vivo
(Frindel & Tubiana, 1968; Bennington, 1969; Young &
DeVita, 1970; Terz et al., 1971; Bresciani et al., 1974).
However, the technique suffers from two major drawbacks.
Firstly, the result is not achieved in a time-scale suitable for
the clinician to use if treatment is to be based on cell kinetic
characteristics. Secondly, its wide use in vivo is precluded due
to ethical considerations involved in administering a radio-
active precursor of DNA and the requirement for multiple
biopsies if cell cycle measurements are to be made.
A technique which allows cell kinetic measurements to be
made on individual human tumours in a time-scale of use to
the clinician in planning the most appropriate treatment, is
that based on the flow cytometric measurement of bromo-
deoxyuridine (BrdUrd) incorporation into DNA (Gratzner,
1982; Dolbeare et al., 1983). We have previously shown that
it is possible to measure the labelling index (LI) of human
tumours following an in vivo injection of BrdUrd, and using
mouse tumours have shown that the BrdUrd technique gives
the same information as the use of 3HTdR (Wilson et al.,
1985). The principal advantages of this flow cytometric
technique are that it is rapid (the result can be obtained
within a day of surgery), it can be used in vivo as BrdUrd is
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not radioactive or toxic at the doses required for cell kinetic
studies, and it is possible to estimate both the LI and the
duration of S-phase (Ts) and hence the potential doubling
time (Tpot) from a single biopsy. The technique to estimate
Tpot is based on the procedure first described by Begg et al.
(1985), whereby a biopsy is taken several hours after an i.v.
injection of BrdUrd.
In this study we describe results of measurements of Tpot
in 26 patients with a variety of solid tumours and show that
the method is applicable to routine measurements of cell
kinetics in human tumours. In addition, we address the
problem of heterogeneity in human tumours by studying
multiple samples in four of the patients.
Materials and methods
Patient selection
Permission to administer BrdUrd was granted by the Ethical
Committee of Mount Vernon Hospital and informed consent
was obtained from each patient. The study included a
spectrum of tumours, both primary and secondary, from the
cervix, rectum, oesophagus, bronchus, head and neck and
two melanomas (see Table I).
BrdUrd adninistration
BrdUrd suitable for in vivo administration to humans was
obtained from the Investigational Drug Division of the Na-
tional Institute of Health, Bethesda, Maryland. Imme-
diately prior to injection 500mg BrdUrd was dissolved in
100ml 0.9% saline and administered by intravenous infusion
over 30min (in our most recent studies the dose of BrdUrd
has been reduced to 200mg and is administered as a single
push in 20ml normal saline). A biopsy or surgical excision
was performed in each case between 4 and 22h after
injection (most were taken between 4 and 8h). No toxicity
was observed in any patient given 500mg BrdUrd in this
manner. In all cases an adjacent portion of material was
examined histologically so that the proportion of the speci-
men occupied by tumour cells, stroma and necrosis could be
estimated.
Cell preparation
The tumours were processed into single cells by a variety of
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methods depending on the nature of the material. The
procedures have been described in detail elsewhere (Wilson
et al., 1985). In general, dissociation by mechanical means
was always attempted first. If this proved unsuccessful, the
tumour fragments were incubated in 0.2% collagenase (type
II, Sigma Chemical Co., Poole, England) and 0.02% DNAse
I (Sigma Chemical Co.) in Hanks Balanced Salt Solution
without calcium or magnesium. More recently, tumours have
been digested with 0.4mgml-1 pepsin in 0.1 M HCI for 1 h at
37°C to release nuclei after prior fixation of solid pieces in
70% ethanol (Schutte et al., 1987).
BrdUrd staining andflow cytometry
The procedures for BrdUrd staining and FCM analysis have
been described in detail previously (Wilson et al., 1985).
Several techniques for DNA denaturation were "tested to
unmask BrdUrd binding sites. The most successful technique
was incubation at room temperature with 2M HCI for 15 to
30min. Procedures involving heat denaturation resulted in
an unacceptable amount of cell loss and clumping. The anti-
BrdUrd antibody used in this study was a rat monoclonal
antibody supplied by Dr. M. Ormerod of the Institute of
Cancer Research, Sutton. The antibody was incubated with
the cells for 1 h at room temperature at a dilution of 1: 25.
Incubation with the second FITC-labelled antibody was for
30min and cells were analysed 15 min after addition of
10pgml-1 propidium iodide (PI) in 3ml PBS. Stained
preparations were analysed by an Ortho Systems 50-H
Cytofluorograph with excitation at 488nm (1OOmW) from
a 5W argon ion laser. Green fluorescence (FITC) was col-
lected between 510-560nm and red fluorescence (PI) above
620nm. Data were collected in list mode and cell doublets,
triplets etc., were excluded from the analysis by gating on
the DNA peak versus area signal. 10,000 to 50,000 cells were
analysed for each specimen.
Results
Table I shows the clinical and histopathological details of
the patients involved in this study. The series included a
spectrum of both primary, recurrent and metastatic tumours
from different sites. Fourteen of the tumours were squamous
cell carcinomas and 6 were adenocarcinomas. The largest
series from an individual site were nine head and neck
tumours (group E).
Figures I and 2 show examples of the staining profiles
obtained several hours after administration of BrdUrd to
patients with solid tumours. Figure lA shows the DNA
profile and 1B the bivariate cytogram of DNA content
versus BrdUrd uptake for a moderately differentiated adeno-
carcinoma of the rectum removed 5.5h after injection of
BrdUrd (patient Cl in Table I). The tumour was aneuploid
(Figure IA) with a DNA index of 1.6. The hyperdiploid
component (i.e. those cells with greater than 2n DNA
content) represented 73% of the total cell population. The
bivariate cytogram (Figure 1B) shows relative green
(BrdUrd) versus red (DNA) fluorescence on a linear scale. In
tumours such as this it can readily be seen that the
proliferative cells are associated with the aneuploid popu-
lation. The LI is defined as the total number of cells in the
population which are synthesising DNA and can be mea-
sured by setting a region around those cells which show
significant BrdUrd incorporation. The lower limit of this
region delineating BrdUrd labelled cells was determined by a
parallel incubation of the cell suspension with the omission
of the anti-BrdUrd monoclonal antibody. In this case the
total LI was 13.7%. An estimate of the aneuploid LI can be
made by setting two regions close to the left edge of the
aneuploid GI population, one around the total number of
aneuploid cells and the other around those cells which show
significant BrdUrd uptake. The LI of the aneuploid cells, in
this tumour, was 17.5%. However, the BrdUrd labelled cells
associated with the aneuploid component are now distri-
buted into two populations. The majority of labelled cells, as
denoted by the rectangular region, are still progressing
through S-phase but show a distribution skewed towards
G2+M. They are clearly separated from BrdUrd labelled
cells which have divided and are now in GI and which are
distinguished from other GI cells by virtue of their BrdUrd
uptake at the time of injection. The division of BrdUrd
labelled cells in the period between injection and biopsy
creates an error in the estimation of the LI as the DNA
precursor will be shared between the two daughter cells at
division. This will lead to an overestimation of the LI which
will increase as the time period between injection and biopsy
increases. The simplest correction would be to calculate the
Table I Clinical details of patients given with BrdUrd for cell kinetic studies
Site of
primary
Cervix
Cervix
Cervix
Rectum
Rectum
Rectum
Rectum
Oesophagus
Oesophagus
Oesophagus
Oesophagus
Larynx
Tongue
Nose/lip
Larynx
Columella
Retromolar
Retromolar
Tongue
Tongue
Bronchus
Bronchus
Bronchus
Supraclavicular
Skin
Skin
Site
biopsied
Primary
Primary
Primary
Recurrent primary
Recurrent primary
Recurrent primary
Recurrent primary
Skin metastasis
Primary
Primary
Recurrent primary
Skin metastasis
Primary
Recurrent primary
Primary
Primary
Primary
Primary
Primary
Recurrent primary
Skin metastasis
Primary
Primary
Recurrent primary
Skin metastasis
Skin metastasis
Histology
Well diff, SCC
Anaplastic small cell
Anaplastic SCC
Moderately diff adenoca.
Papillary well diff adenoca.
Moderately diff adenoca.
Moderately diff adenoca.
Moderately diff adenoca.
Moderate to poor diff adenoca.
Poorly diff SCC
Poorly diff SCC
Poorly diif SCC
Very well diff SCC, verrucal.
Well diff SCC
Hyperkeratotic papilliferous SCC
Well diff keratinising SCC
Moderately diff SCC
Well diff SCC
Moderate diff keratinising SCC
Moderately diff SCC.
Oat cell ca.
Poorly diff SCC, keratinising
Oat cell ca.
Diffuse non-Hodgkins lymphoma
Malignant melanoma
Malignant melanoma
Code
BI
B2
B3
Cl
C2
C3
C4
DI
D2
D3
D4
El
E2
E3
E4
E5
E6
E7
E8
E9
Fl
F2
F3
HI
I1
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Figure 1 DNA profile (a) and bivariate cytogram (b) of BrdUrd
uptake versus DNA of patient Cl. The tumour was a moderately
differentiated adenocarcinoma of the rectum. The biopsy was
removed 5.5 h after BrdUrd administration. The DNA profile
was aneuploid with an index of 1.6. The region in (b) denotes the
population of cells still progressing through the cell cycle towards
G2+M from which the Ts measurement is made.
number of BrdUrd labelled cells which had divided (both in
the diploid and the aneuploid populations) and subtract half
of this number from the total number of labelled cells and
from the total number of cells. This, however, may lead to
an underestimation of the true LI as it does not take into
account unlabelled G2 cells which will also have divided and
expanded the cell population at the time of biopsy. If it were
also possible to estimate the number of G2 cells which had
divided then a better estimate of the true LI could be made.
However this is not possible because the unlabelled cells in
GI at the time of biopsy will be a mixture of cells that were
in GI at the time of labelling that have not yet progressed
into S and G2 cells that have divided. Consequently, we
have corrected the LI simply by halving the number of
labelled cells which have divided. This correction reduces the
LI to 12.4 and 16.0% in the total cell and hyperdiploid only
populations, respectively, in Figure IB. The estimation of Ts
from profiles such as this was made using the technique
described by Begg et al. (1985). In this analysis the mean
DNA content of the BrdUrd labelled cells still progressing
through S-phase (i.e. those cells in the rectangular region) is
expressed as a proportion of the difference in DNA content
between Gl and G2+M cells. This is achieved by measuring
the mean DNA content of GI and G2+M cells either from
the bivariate cytogram or the DNA profile and the mean
DNA content of the BrdUrd labelled cells which are still
progressing through S and have not yet divided. The 'relative
movement' (R.M.) is then calculated by subtracting the
mean DNA of Gl cells from that of the S-phase population
and dividing it by the GI DNA content subtracted from the
G2 DNA content. In order to make the calculation of Ts
from the R.M., three assumptions are made: firstly, that
immediately after injection with BrdUrd, the labelled S-phase
cells are evenly distributed throughout S-phase with a mean
DNA content in mid-S, giving a relative movement of 0.5;
secondly, that the R.M. reaches 1.0 when those labelled cells
that had just entered S-phase reach G2; i.e. in a time equal
to Ts; thirdly, that the R.M. is a linear function of time. It is
then possible to calculate Ts from a single measurement of
R.M. at some time after pulse labelling with BrdUrd. In
Figure lB the R.M. was 0.61 giving a Ts of 25.8h. Using
this value and the LI of 16.0%, the potential doubling time
(Tpot) can be calculated from the relationship; Tpot=A. Ts/
LI, where A is a correction factor for the age distribution of
the population. A value of 0.8 was used in these calculations
(see Steel, 1977), giving a Tpot of 5.4 days in this tumour.
Figure 2 shows the profiles obtained from a malignant
melanoma biopsied 7h after BrdUrd injection (Patient II in
Table I). The DNA profile (Figure 2A) shows that the cell
population was diploid. The striking feature of this specimen
was that the majority of BrdUrd labelled cells: had divided
and entered GI in 7h. The Ts measurement gave a value of
8.8h and this, in conjunction with a corrected LI of 8.3%,
gave a Tpot of 3.2 days. This is extremely short, implying
very rapid proliferation in this tumour.
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Figure 2 DNA profile (a) and bivariate cytogram (b) of BrdUrd
uptake versus DNA of patient I1. The tumour was a malignant
melanoma. A skin nodule was removed 6.5h after BrdUrd
administration. It is evident from (b) that the majority of
labelled cells have divided and are now in GI.
Table II summarizes the cell kinetic data we have obtained
in the series of 26 evaluable patients using this technique.
Fourteen of the patients (54%) had aneuploid tumours. The
numbers are too small to assess whether there is a significant
relationship between differentiation and DNA ploidy in this
series. However, Figure 3A shows that of 14 squamous cell
carcinomas from various sites only 1 of 5 well differentiated
tumours was aneuploid whilst only 1 of 8 moderate or
poorly differentiated tumours was diploid. There was no
relationship between differentiation and potential doubling
time in this group of tumours (Figure 3B). In 6 adeno-
carcinomas, the only well differentiated tumour was diploid
and the only poorly differentiated tumour was aneuploid.
The total cell population LI of all tumours in this study
ranged from 2.3 to 20.6% with a median value of 6.4%.
Eight tumours (31%) had a total LI of 10% or greater; 4
were aneuploid and 4 diploid. The median total LI of
diploid tumours (n =12) was 8.3% compared to 5.7% in the
aneuploid tumours (n=14). The median LI in aneuploid
tumours was increased to 10.0% when the measurement was
made on the hyperdiploid population only. Using this refine-
ment, the number of tumours with LIs of 10% or greater
increased to 11 (42%), and of these 7 were aneuploid and 4
diploid.
The Ts measurements in this series of patients ranged
from 5.8h to 30.7h, the median value being 16.2h. Five
tumours had a Ts of less than 10 h. Three of these were head
and neck tumours whilst the other two were melanomas.
Figure 4 shows the mean Ts values for each of the groups of
tumours. Although the numbers are quite small in each
group of tumours apart from the head and neck patients,
there appears to be a trend for tumours of the same origin
to have a similar Ts. Consequently, Figure 4 shows the mean
rather than median value of Ts together with the s.e.m.
(solid bars) and range (dotted bars) to give an indication of
the variation in this parameter between different groups of
tumours. Figure 4 shows that there are striking differences in
Ts from tumours of different sites. There is a gradation in Ts
throughout the upper aerodigestive tract. Head and neck
tumours have a short DNA synthetic period (mean
11.8+1.2h). Tumours from oesophageal sites all had very
similar Ts values (mean 16.5+0.4h) whilst lung tumours had
longer S-phases (24.3+2.7h). Rectal tumours tended to have
a long Ts (24.5+2.9h) whilst the two melanomas had the
shortest Ts values (8.8 and 8.7h).
The calculated potential doubling times ranged from 3.2
days in an oat cell carcinoma (Fl) to 23.2 days in a
lymphoma (HI). The median Tpot was surprisingly short at
5.6 days. Ten tumours (38%) had a Tpot of less than 5 days;
of these 7 were aneuploid.and 3 diploid. Figure 5A shows
the relationship between total LI and measured Tpot. Dotted
lines have been drawn through a LI of 10% and a Tpot of 5
days. These are 'threshold' values, below which patients may
benefit from a reduction in overall treatment time (Fowler,
1985, Thames et al., 1983). If the LI were the only parameter
measured, as was the case in previous studies with 3HTdR,
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Table II Cell kinetic parameters of patients injected with BrdUrd in vivo. The
aneuploid LI was calculated by excluding cells with 2n DNA content (both
BrdUrd labelled and non-labelled cells). The Tpot measurements are calculated
using the total LI in diploid tumours and the aneuploid population LI in
aneuploid tumours.
Total LI Aneuploid Ts Tpot
Code DNA index (%) LI (%) (hr) (days)
Bi 2.4 15.2 17.0 22.0 4.3
B2 2.1 6.6 15.7 20.8 4.4
B3 1.6 5.6 11.0 11.8 3.6
Cl 1.6 12.4 16.0 25.8 5.4
C2 1.0 10.3 30.7 9.9
C3 1.0 14.7 25.0 5.7
C4 1.0 10.7 16.6 5.2
DI 1.3 5.5 14.2 15.6 3.7
D2 1.7 5.8 7.6 16.7 7.3
D3 2.6 2.5 6.4 17.5 9.1
D4 1.8 6.1 8.0 16.3 6.8
El 1.0 8.3 18.8 7.6
E2 1.0 2.9 5.8 6.7
E3 1.0 8.9 13.3 5.0
E4 1.0 7.8 9.5 4.1
E5 1.0 3.4 12.5 12.3
E6 1.5 12.8 13.2 13.3 3.4
E7 1.0 4.6 10.9 7.9
E8 2.0 5.0 9.1 12.5 4.6
E9 1.4 3.2 7.3 9.7 4.4
Fl 1.0 20.6 20.0 3.2
F2 1.6 4.3 13.8 29.4 11.3
F3 1.2 11.9 14.5 23.4 5.7
HI 1.0 2.3 16.0 23.2
I1 1.0 8.3 8.8 3.5
12 1.7 3.4 4.2 8.7 6.9
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Figure 3 Relationship between histological assessment of differ-
entiation and DNA ploidy (a) or Tpot (b) in 13 squamous cell
carcinomas from a variety of different sites.
Figure 4 Ts measurements of tumours from different sites. The
results are presented as mean +s.e.m. (solid lines) and range
(dotted line) for each tissue.
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then 13 patients would have been wrongly classified into the
'rapid' or 'slow' proliferating groups. Eight of these were
patients whose tumours had LIs less than 10% but Tpots of
less than 5 days; the other five had high LIs but longer
Tpots. Figure 5B shows that the situation was only slightly
improved when the aneuploid LI was used, where it was
measurable. Five patients remained in the low LI short Tpot
group and 5 in the higher LI long Tpot group. All 4 cases of
rectal carcinoma fell into the group of high LI but long Tpot
whilst 4 cases of head and neck tumours were found in the
low LI short Tpot group. This demonstrates the dependence
of Tpot on Ts.
Any procedure which is based upon measurements from a
single small biopsy suffers from the criticism that the biopsy
may not be representative of the whole tumour. We have
addressed this problem in four of the tumours, in which it
was possible to take several samples. Figure 6 shows the
results obtained for patient B3. The specimens consisted of
four samples selected at random by the pathologist from a
large surgically resected tumour of the cervix; histologically
the four pieces all contained anaplastic squamous carcinoma
cells but there were differences in the amount of stromal and
of necrotic areas. Figure 6a shows the relative amounts of
tumour, stroma and necrosis in each sample, estimated
histologically, and should be compared with Figure 6b in
which the percentage of 'tumour' cells (i.e., those with
greater than 2n DNA content) has been measured by FCM
analysis of the DNA profile. Qualitatively the variation in
the presence of aneuploid cells matched the histological
assessment of the amount of tumour in each sample. Sample
2 had the least tumour histologically and the smallest
fraction of aneuploid cells. The variation in the presence of
aneuploid cells between samples is reflected in the variation
in total LI (Figure 6c). This ranged from 4.3 to 7.3% with a
mean of 5.6+0.7%. The aneuploid LI (calculated excluding
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Figure 5 Correlation between LI and the measured Tpot. The
total cell population LI, of both diploid and aneuploid tumours,
is shown in (a). In (b) the LI of the 14 aneuploid tumours (solid
symbols) has been calculated excluding the normal Gl; the LI of
the 12 diploid tumours (open symbols) remains as in (a). The
dotted lines represent the cut-off denoting 'rapidly' or 'slowly'
proliferating tumours for each parameter.
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Figure 6 Heterogeneity in cell kinetic parameters from a patient
with an anaplastic squamous cell carcinoma of the cervix (b3).
The histograms represent individual values for histological assess-
ment of percent of tumour E1, stroma U and necrosis *(a), %
of hyperdiploid cells (b), total LI (c), aneuploid LI (d), Ts (e)
and Tpot (f) obtained from each of 4 samples.
the diploid Gl) showed less variation (Figure 6d), with a
mean of 11.0+0.9%. There was very little difference in the
estimate of Ts between the samples (range 10.5 to 12h)
(Figure 6e) with the result that the variation in the calcu-
lated potential doubling time reflected, primarily, variations
in the LI between samples. This ranged from 2.9 to 4.6 days
with a mean of 3.6+0.4 days (Figure 6f). There was no
change in the DNA index between the samples (results not
shown).
Figure 7 shows results obtained in patient C4. This patient
had previously undergone a resection and anastomosis for
carcinoma of the rectum. The specimens removed for this
study came from a recurrence in the rectal stump. Four
areas of the tumour were sampled as was a polypoid
fragment. All samples, including the tissue from the polypoid
region, showed similar histology with presence of a modera-
tely differentiated and partly mucin secreting adeno-
carcinoma similar to the primary. The DNA content of the
specimens was diploid. In this patient, there was variation in
both the LI (Figure 7a) and Ts (Figure 7b) and, hence, the
Tpot (Figure 7c) measurements between the individual sam-
ples. The LI ranged from 8.9 to 13.1% and the Ts from 13
to 19h in the biopsies from the main tumour area which
resulted in a range of Tpot of 3.4 to 6.9 days. The cell
kinetic characteristics of the tumour tissue from the polypoid
area was markedly different to the other samples; the LI was
8.7% and the Ts 31.9h giving a Tpot of 12.2 days.
The other two patients, D4 and H1, did not show any
significant difference in cell kinetic parameters between
different biopsies. Six biopsies were processed from patient
H1; all 6 showed similar histology with the presence of
diffuse grade II non-Hodgkin's lymphoma. The tumour was
diploid and the LI and Ts ranged from 2.2 to 2.5% and 14.7
to 16.7h, respectively. The estimates of Tpot ranged from
21.3 to 25.3 days (Figure 8). Patient D4, had a poorly
differentiated infiltrating SCC of the oesophagus which
extended to the surrounding connective tissue. Two areas
were studied, one sample was taken from the lumen surface
and the other from the area infiltrating the connective tissue;
these specimens showed similar histology. The tumour was
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Figure 7 Heterogeneity in cell kinetic parameters from a patient
with a moderately differentiated adenocarcinoma of the rectum
(C4). The histograms represent individual values of LI (a), Ts (b)
and Tpot (c) obtained from 4 areas of the tumour and a
polypoid fragment.
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aneuploid, but there were no significant differences in DNA
index, % of hyperdiploid cells, total LI, aneuploid LI, Ts or
Tpot (Figure 9).
Discussion
This study demonstrates the feasibility of making routine
measurements of cell kinetics in solid human tumours using
BrdUrd administration and FCM. The technique offers
obvious advantages over previous techniques using 3HTdR
and autoradiography. Labelling can be done in vivo without
the problems associated with the administration of radio-
active material to patients or multiple sampling. BrdUrd is
non-toxic at the dose (500mg) used in these studies, and we
have recently reduced this dose to 200mg without any loss
of resolution of the BrdUrd profiles; doses as high as
1,000mgm-2 day - for up to 2 weeks have been adminis-
tered to patients in radiosensitization studies with no acute
toxicity (Kinsella et al., 1984). In addition, the results can be
obtained within a day.
Ten patients who were administered BrdUrd failed to give
a satisfactory result (data not shown). However, in 7 of the
cases that failed there were too few viable cells in the biopsy
either because of extensive necrosis or the biopsy was too
small to give sufficient cells for FCM (at least I million cells
at the start of staining are required). There were 3 cases in
which the BrdUrd staining failed for no apparent reason.
The parameters that can be measured from a single biopsy
are the LI, Ts and thus Tpot. The potential doubling time is
the doubling time of a population of cells taking into
account the growth fraction but ignoring cell loss. There is
evidence in both animal and human tumours that repopu-
lation rates during or after radiotherapy are similar to the
potential doubling time. Maciejewski et al.. (1983) showed
that local control of T3/4 larynx cancer fell from acceptable
levels when the overall treatment time was extended beyond
6 weeks. The dose to control 50% of the tumours increased
by about 0.5 Gy per day which is consistent with a
population doubling time of about 4 days. This is similar to
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Figure 8 Heterogeneity in cell kinetic parameters from a patient
with a diffuse non-Hodgkin's lymphoma (HI). The histograms
represent individual values of LI (a), Ts (b) and Tpot (c) from
six areas of the tumour.
100
5n
0
8
6
4
2
0
1 2
-0
0. 5
_ C
>. 0
I 1 2
Biopsy
a d
CO
0
U)
co
-0
4-
0
CO
f
x
a)
-0
z
0l
Biopsy
Figure 9 Heterogeneity in cell kinetic parameters from a patient
with a poorly differentiated SCC of the oesophagus (D4). The
histograms represent individual values of % of hyperdiploid cells
(a), total LI (b), hyperdiploid LI (c), Ts (d), Tpot (e) and DNA
index (f) from an area abutting the lumen of the bronchus (1)
and an area infiltrating the connective tissue (2).
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cavity. This range of v
vations made in our study with head and neck tumours. We
have not attempted this technique in solid tumours but in
collaboration with Riccardi et al. (1988), we have shown that
in 13 cases of haematological disease where Ts was measured
U. .o simultaneously by the double labelling technique of Dormer
-- -z (1973) and the BrdUrd/DNA staining method the two
o estimates were similar (correlation coefficient 0.83, P<0.05).
E In that study there was also a good correlation between
-~ BrdUrd LI and 3HTdR LI measured simultaneously in 48
patients with haematological tumours or normal bone
marrow (r=0.91, P<0.05).
. It is difficult to assess if LI measurements in vivo agree
10 20 30 with those obtained from in vitro techniques because of
Corrected LI (%) patient selection procedures. Our previous study (Wilson et al., 1985) using in vitro BrdUrd incorporation, and unpub-
lished observations, showed a median total LI of 5.0% in 26
cases of colorectal cancer whilst in four cases in vivo in this
present study, the median was 11.6%. In 75 measurements
from all tumour types, in vitro, the overall median LI was
5.3% whilst the median LI in this present in vivo study of 26
patients was 6.4%. Any differences could reflect shortcom-
ings in achieving complete incorporation of DNA precursors
into tumour fragments in vitro. Differences were observed, to
some extent, in a study by Chavaudra et al. (1979). These
authors measured LI in vivo and in vitro simultaneously in 16
human solid squamous cell carcinomas of the head and neck
using either incubation with or injection of 3HTdR. The
mean LI in vivo was 16.3% whilst that in vitro was only
10 20 11.5%. They showed that in 10 of the tumours there was
reasonable agreement between the two methods but that
,orrected TPOT (days) there was serious underestimation of LI by in vitro labelling
ed in LI (a) and Tpot (b) if correction in the other 6 tumours. The overall conclusion, from their
labelled cells between injection and study, was that in vitro techniques may lead to an under-
estimation of LI due either to heterogeneity from one biopsy
to another in the same tumour or a lower uptake of DNA
precursor in the deep cell layers of the in vitro labelled
ime of the untreated tumours calcu- tumour fragments. If heterogeneity was the problem, then
3HTdR LI of 15% observed in one might have expected the variation between in vivo and in
as of the head and neck, assuming a vitro LI to have been more random. This data and our own
ummermehr, 1985). Parsons et al. data suggests that in vitro labelling is underestimating the
al control and 5 year survival, for true labelling index. This study and our previous study
neck cancer, improved if 30 fractions (Wilson et al., 1985) have demonstrated the presence of a
,ompared to 30 fractions in 8 weeks significant proportion of S-phase cells which do not appear
the middle. An average improvement to take up BrdUrd. In this study we are not able to estimate
cal control for all stages of disease. the relative proportions of these two populations as we are
increase in effective dose and an delaying the biopsy after injection such that at the time we
:11 kill. This corresponds to at least 3 make our observation there will be cells in S-phase which do
ier in 2 weeks (Fowler, 1985). This not show BrdUrd uptake because they were in GI at the
' the value of Tpot mentioned above. time of the injection. It is apparent that this population of S-
.tion rates of human tumours can be phase cells varies from tumour to tumour and can be as
time to local recurrence after poten- small as only a few percent of the total S-phase population
apy (Thames et al., 1983), assuming or can be as great as 50%. The identity and significance of
of uncontrolled tumours starts from these cells has yet to be established. The lack of BrdUrd
nic cells. Using this approach, Trott uptake might be due to failure to be exposed to the DNA
showed that the tumour groups with precursor or to arrest or slowing down of DNA synthesis
sured from in vitro 3HTdR LIs and due to changing microenvironments. There has been recent
had the longest latency period to evidence (Chaplin et al., 1987) to suggest that there may be
e-versa for the short Tpots. transient opening and closing of blood vessels in tumours
;urements made in this study agree leading to foci of hypoxia. Such a mechanism could result in
data available in the literature. Most our observation of unlabelled S-phase cells as some cells may
vent labelled mitosis curve technique not see the BrdUrd as vessels around them were closed at
(1977). From a variety of different the time of injection or because they had become temporarily
Lnd pleural effusions, the average Ts arrested due to hypoxia. The question then arises whether
from 11 h in a carcinoma of the these unlabelled cells are functional or could become
et al., 1971) to 25 h in a melanoma functional.
) and a neuroblastoma (Wagner & We have calculated the potential doubling time according
of these studies the criterion for to the simple procedure described by Begg et al. (1985) with
that very advanced stage disease was the assumptions as indicated above. In spite of the more
en a report by Japanese workers detailed mathematical considerations in the appendix of the
ig Ts in solid tumours by an in vitro paper by Begg et al. (1985) and by White & Meistrich (1986)
ae with high and low specific activity we have found the assumption of linearity in the change
) measured Ts values ranging from in R.M. with time to be a reasonable one in cells in culture,
iquamous cell carcinomas of the oral in mouse bone marrow, in cells of the mouse kidney and in
values is very similar to the obser- two transplantable mouse tumours (Begg et al., 1985, Wilson
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et al., 1987; Wilson & McNally, unpublished observations).
In all but one of these cases the initial value of the R.M. was
not significantly different from 0.5. For one tumour (SAF) it
was closer to 0.4. Of course it has not been possible to make
comparable measurements in human tumours.
A potential source of error in measuring the LI arises
through cell division in the time between injecting the
BrdUrd and taking the biopsy. The larger this time, the
greater the error will be. We have made the simplest, and
probably only technically feasible, correction of halving the
number of BrdUrd labelled cells that appear in GI, as
described above. Figure 10 shows the effect of not making
this correction on both the LI (A) and Tpot (B). The
number of tumours with a LI of greater than 10%, increased
from 12 to 17 if the correction was not made and the
number of with a Tpot of 5 days or less increased from 11
to 14. The greatest effect of not making the correction was
in those tumours with the longest interval between injection
and biopsy and in those which had a very short Ts. If the
time interval is too short, however, it may be difficult to
detect a significant movement of BrdUrd labelled cells
towards G2. Based on these limited results, we feel that
intervals of 3 to 4h for melanomas and head and neck
tumours, and between 6 to 8h for other tumour types may
be most suitable.
The technique we have used to measure Tpot is based on
measurements from a single biopsy. It is important, there-
fore, to try and assess the potential error due to hetero-
geneity within individual tumours with respect to their cell
kinetics. We have addressed this problem in four of the
patients we have studied. There were no differences in the
cell kinetic parameters measured in six samples from a non-
Hodgkin's lymphoma (Figure 8) or two biopsies from a SCC
of the oesophagus (Figure 9). There were some variations in
an aneuploid SCC of the cervix (patient B3, Figure 6). The
greatest variation was in the total LI which varied from 4.3
to 7.3%. However, this was largely a reflection of variations
in the extent of normal stromal tissue in each sample which
were seen histologically and in the flow cytometer as varia-
tions in the fraction of the population that was hyperdiploid
(Figure 6b). When the potential doubling time was calcu-
lated excluding the 'normal' GI cells, there was relatively
little variation from one sample to the next (mean Tpot 3.6
days, range 2.9 to 4.6 days, Figure 6f). This example
illustrates the importance of having parallel histology of
tissue adjacent to pieces processed for FCM. Indeed, not
only can the FCM analysis be related to the histology, but
BrdUrd incorporation can also be assessed in the tissue
section by immunohistochemical staining (Wilson et al.,
1988). In these three cases the main differences in cell
kinetics from one sample to the next were in the LI with
relatively small differences in the estimate of Ts. However, in
the five samples from the recurrent carcinoma of the rectum
(patient C4, Figure 7), there was variation in both LI and
Ts. In particular, the tissue taken from the polypoid frag-
ment showed a much longer Ts (30.9h) than the other four
samples from the main bulk of the tumour which ranged
from 13.2 to 19.3 h. The reason for this is unclear as there
was no histological difference in the tumour from the two
areas. These differences, in conjunction with variation in the
LI (range 8.7 to 13.1%), resulted in a large range of Tpot
throughout this tumour (3.4 to 9.8 days). Although parallel
histology was not processed for each sample, the specimen
was moderately differentiated and consisted of approxi-
mately 50% tumour cells and 50% normal stromal cells. It is
possible that there were differences in the pattern of cellu-
larity of each sample which could account tor the observed
differences.
It would appear, from these four examples, that the
principal source of variation between different samples is the
LI. This, in turn, is reflected in relatively small variations in
the estimated Tpot in all but one of the cases we have
studied. Certainly, from a predictive point of view the
variation we have measured would not be serious. If, for
instance, patients were going to be selected for accelerated
fractionation based on their kinetic parameters, one would
not need to have a sharp delineation in the value of Tpot
below which patients would be given the altered treatment
and above which they would not. If a Tpot of 3.4 days was
estimated and the true value was 7 days, the selection for
accelerated fractionation would almost certainly not com-
promise the outcome (and vice versa).
The estimates of Tpot in this group of patients are striking
because of the proportion of tumours which had the poten-
tial for rapid proliferation. Thirty-eight percent of the
tumours in this study (from all the sites) had Tpots of less
than 5 days. The shortest Tpot of 3.2 days was seen in a
patient with metastatic oat cell carcinoma. Seven of the 16
patients with tumours of the head and neck, oesophagus or
bronchus, sites accessible for biopsy and suitable for acceler-
ated fractionation, had Tpots of less than 5 days. These
estimates of Tpot are similar to the few that can be
computed from the data collected by Steel (1977).
Using the median Ts, the LI and a correction factor of
0.8, then the cases reported by Steel ranged from 1.3 days in
a tumour of the maxillary antrum (Terz et al., 1971) to 11.7
days in a reticulum cell sarcoma (Peckham & Steel, 1972).
The study by Sakuma (1980) reports very short Tpots, in
carcinoma of the oral cavity, ranging from 0.7 to 2 days. In
radiotherapy, it has been calculated that if overall treatment
times of 6 or 7 weeks are shortened to one half or one third
by using 2 or 3 fractions per day then gains in local control
can be achieved if the doubling time of clonogenic tumour
cells is 5 days or shorter (Thames et al., 1983). The rationale
behind this approach is that if tumours are repopulating
rapidly, then reducing the overall treatment, for instance by
21 days, will save 4.2 cell doublings in tumours with
clonogenic doubling times of 5 days or less. This corres-
ponds to a factor of 18 decrease in the number of cells which
have to be killed by the treatment.
For patients to benefit from an altered treatment schedule,
such as accelerated fractionation, it is important that cell
kinetic information can be obtained with the minimum
inconvenience to the patient and in a timescale useful to the
clinician in selecting the appropriate treatment. The tech-
nique described here can obtain the relevant information
within a day of biopsy without undue stress to the patient.
The value of pretreatment cell kinetic measurements has yet
to be verified in radiotherapy. Accelerated fractionation
employing 3 treatments each day for a continuous period of
12 days is currently being employed at Mount Vernon
Hospital to treat advanced head and neck and bronchial
tumours (Saunders & Dische, 1986) with favourable regres-
sion and remission rates compared to previous studies.
Whenever possible, patients receiving this treatment are now
having their pretreatment cell kinetics measured. In future
randomised controlled trials of accelerated fractionation,
measurements of Tpot as we have described should be
included in both arms of the trial. If it is shown that
tumours with short potential doubling times are best treated
in an accelerated course of radiotherapy, then there will be
important implications, not only for the patients receiving
radiotherapy but, also for those being managed by cytotoxic
chemotherapy where rapid repopulation between cycles of
treatment would have a similarly harmful influence upon
tumour control, and measurements of Tpot should become
part of the routine characterisation of the tumour before
treatment.
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